These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 1829146)

  • 1. Reversal of left ventricular hypertrophy following recombinant human erythropoietin treatment of anaemic dialysed uraemic patients.
    Cannella G; La Canna G; Sandrini M; Gaggiotti M; Nordio G; Movilli E; Mombelloni S; Visioli O; Maiorca R
    Nephrol Dial Transplant; 1991; 6(1):31-7. PubMed ID: 1829146
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Renormalization of high cardiac output and of left ventricular size following long-term recombinant human erythropoietin treatment of anemic dialyzed uremic patients.
    Cannella G; La Canna G; Sandrini M; Gaggiotti M; Nordio G; Movilli E; Maiorca R
    Clin Nephrol; 1990 Dec; 34(6):272-8. PubMed ID: 2073771
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of recombinant human erythropoietin treatment on left ventricular hypertrophy and cardiac function in dialysis patients.
    Massimetti C; Pontillo D; Feriozzi S; Costantini S; Capezzuto A; Ancarani E
    Blood Purif; 1998; 16(6):317-24. PubMed ID: 10343078
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of long-term amelioration of anemia and blood pressure control on left ventricular hypertrophy in hemodialyzed patients.
    Zehnder C; Zuber M; Sulzer M; Meyer B; Straumann E; Jenzer HR; Blumberg A
    Nephron; 1992; 61(1):21-5. PubMed ID: 1388250
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regression of left ventricular hypertrophy after partial correction of anemia with erythropoietin in patients on hemodialysis: a prospective study.
    Pascual J; Teruel JL; Moya JL; Liaño F; Jiménez-Mena M; Ortuño J
    Clin Nephrol; 1991 Jun; 35(6):280-7. PubMed ID: 1831414
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Improvement of left ventricular hypertrophy by anemic-correcting erythropoietin therapy in chronic renal insufficiency].
    Jiang JP; Hou FF; Gao LZ; Pan YB; Yang NS; Chen W; Shu GY; Chen YM; Chen J; Peng WH; Wu JP; Yang ZM
    Zhonghua Nei Ke Za Zhi; 2005 Jan; 44(1):25-9. PubMed ID: 15769393
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effects of maintenance recombinant human erythropoietin therapy on ambulatory blood pressure recordings: conventional, Doppler, and tissue Doppler echocardiographic parameters.
    Kirkpantur A; Kahraman S; Yilmaz R; Arici M; Altun B; Erdem Y; Yasavul U; Turgan C
    Artif Organs; 2005 Dec; 29(12):965-72. PubMed ID: 16305652
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Regression of left ventricular hypertrophy in dialysis patients following correction of anemia with recombinant human erythropoietin.
    Silberberg J; Racine N; Barre P; Sniderman AD
    Can J Cardiol; 1990; 6(1):1-4. PubMed ID: 2138048
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vascular changes in hemodialysis patients in response to recombinant human erythropoietin.
    London GM; Zins B; Pannier B; Naret C; Berthelot JM; Jacquot C; Safar M; Drueke TB
    Kidney Int; 1989 Nov; 36(5):878-82. PubMed ID: 2615194
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Follow-up of cardiac changes induced by anemia compensation in normotensive hemodialysis patients with left-ventricular hypertrophy.
    Wizemann V; Schäfer R; Kramer W
    Nephron; 1993; 64(2):202-6. PubMed ID: 8321352
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term myocardial effects of correction of anemia with recombinant human erythropoietin in aged patients on hemodialysis.
    Martinez-Vea A; Bardají A; García C; Ridao C; Richart C; Oliver JA
    Am J Kidney Dis; 1992 Apr; 19(4):353-7. PubMed ID: 1532883
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hemoglobin response and influence on left ventricular hypertrophy after 24-week treatment of a biosimilar epoetin-alfa in hemodialysis patients with anemia.
    Thanakitcharu P; Siriwiwatanakul N
    J Med Assoc Thai; 2007 Dec; 90(12):2574-86. PubMed ID: 18386706
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Haemodynamic changes induced by the correction of anaemia by erythropoietin: role of antiplatelet therapy.
    Caravaca F; López-Minguez JR; Arrobas M; Cubero J; Pizarro JL; Cid MC; Sanchez-Casado E; Miranda MP
    Nephrol Dial Transplant; 1995; 10(9):1720-4. PubMed ID: 8559495
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term effects of treatment with recombinant human erythropoietin on haemodynamics and tissue oxygenation in patients with renal anaemia.
    Nonnast-Daniel B; Deschodt G; Brunkhorst R; Creutzig A; Bahlmann J; Shaldon S; Koch KM
    Nephrol Dial Transplant; 1990; 5(6):444-8. PubMed ID: 2122322
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Platelet aggregation during the recombinant human erythropoietin (rHuEPO) treatment of patients with uremia].
    Mazerska M; Pawlak K; Azzadin A; Małyszko J; Małyszko J; Myśliwiec M; Buczko W
    Pol Arch Med Wewn; 1992 Oct; 88(4):230-7. PubMed ID: 1488323
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cardiovascular abnormalities in end stage renal failure: the effect of anaemia or uraemia?
    Morris KP; Skinner JR; Hunter S; Coulthard MG
    Arch Dis Child; 1994 Aug; 71(2):119-22. PubMed ID: 7944530
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Haemodynamic changes and exercise tolerance in dialysis patients treated with erythropoietin.
    Jurić M; Rupcić V; Topuzović N; Jakić M; Brlosić R; Rusić A; Karner I; Stipanić S; Kes P
    Nephrol Dial Transplant; 1995; 10(8):1398-404. PubMed ID: 8538932
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Changes in left ventricular size, wall thickness, and function in anemic patients treated with recombinant human erythropoietin.
    Goldberg N; Lundin AP; Delano B; Friedman EA; Stein RA
    Am Heart J; 1992 Aug; 124(2):424-7. PubMed ID: 1386184
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of erythropoietin on cardiovascular prognosis parameters in hemodialysis patients.
    Frank H; Heusser K; Höffken B; Huber P; Schmieder RE; Schobel HP
    Kidney Int; 2004 Aug; 66(2):832-40. PubMed ID: 15253740
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The cardiovascular and hemodynamic effects of erythropoietin in chronic renal failure.
    Singh NP; Chandrashekhar ; Nair M; Anuradha S; Kohli R; Agarwal SK
    J Assoc Physicians India; 2000 Mar; 48(3):301-6. PubMed ID: 11229114
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.